![]() |
市场调查报告书
商品编码
1541120
2024-2032 年按产品、应用、最终用途和地区分類的病毒过滤市场报告Virus Filtration Market Report by Product, Application, End Use, and Region 2024-2032 |
2023年全球病毒过滤市场规模达43亿IMARC Group。全球健康危机的发生率不断上升,在紧张的工期内大规模生产生物製药的需求不断增长,以及对新药、疗法和疫苗开发的投资不断增加,是推动市场成长的关键因素。
病毒过滤是生物製药生产过程中的关键步骤,旨在确保疫苗、抗体和生物製剂等医药产品的安全性和纯度。此方法用于去除可能对人类健康有害的病毒污染物。它在註射药物的生产中尤其重要,因为注射药物会直接进入体内,因此需要高纯度标准。通常,使用具有特定孔径的专用薄膜过滤器来捕获和去除病毒。这些过滤器旨在允许所需产品通过,同时有效捕捉病毒颗粒。该流程在实施前经过严格验证,并定期进行测试以确认其有效性。此外,它还可以作为药品生产的强大保障,提高产品安全性和符合法规要求。
全球市场主要受到流行病和广泛病毒爆发等全球健康危机不断升级的推动。这凸显了这种过滤技术对于确保医疗用品和药品安全的重要性。在此期间,对疫苗和其他治疗剂的需求呈指数级增长。这项需求使得生物製药必须在紧迫的时间内进行大规模生产,同时又不影响安全性。因此,这对市场有正面影响。除此之外,生物製药产业合约製造组织(CMO)的兴起是促进市场成长的另一个重要因素。此外,对新药物、疗法和疫苗开发的投资不断增加,这些投资本质上需要这些流程来确保安全性和合规性,这也极大地支持了市场。
对生物製药的需求不断增加
病毒过滤产业的重要市场驱动力之一是对单株抗体、重组蛋白和疫苗等生物製药的需求不断增长。这些复杂的分子通常源自活细胞,使它们容易受到病毒污染。同时,癌症、糖尿病和自体免疫疾病等慢性疾病盛行率的上升正在影响市场。需求的成长给製造商带来了生产符合严格安全和品质标准的生物製药的负担。在这种情况下,病毒过滤成为不可或缺的步骤,因为它对于确保这些产品的纯度和安全性至关重要。监管机构正在製定严格的病毒清除指南,进一步强调了这些技术的重要性。随着越来越多的生物製药进入市场或进行临床试验,对病毒过滤服务的需求也随之加速,从而推动产业向前发展。
技术和研究的不断进步
过滤膜和方法领域的技术进步正在显着影响病毒过滤产业的成长。同时,更有效率、可扩展且更具成本效益的过滤系统的开发使製药公司更容易将这些解决方案整合到其现有的生产线中。奈米技术和材料科学的创新使过滤器具有更高的效率和更好的吞吐能力,从而能够更快速、更可靠地去除病毒。随着过滤技术的研究和开发工作不断进行,该领域的公司正在增加该技术的采用。这项技术进步提高了药品製造的水平,并为全球市场提供了强大的市场驱动力。
更加重视法规遵从性和品质保证
遵守监管标准是病毒过滤产业的要求和市场驱动力。各机构对生物源医药产品的病毒安全性有具体的指导方针。这些指南通常需要采取多个步骤来清除病毒,包括病毒过滤。满足这些监管期望对于製药公司获得产品批准和维持市场信誉至关重要。考虑到病毒污染的可怕后果,从产品上市延迟到法律责任,对监管合规性的重视成为采用病毒过滤技术的强制力量。此外,该行业受益于对品质保证的高度关注,使其成为生物製药製造价值链的重要组成部分。
The global virus filtration market size reached US$ 4.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.2 Billion by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032. The rising occurrences of global health crises, the growing need for mass production of biopharmaceuticals under tight schedules, and the growing investments in the development of new medicines, therapies, and vaccines are among the key factors driving the market growth.
Virus filtration is a critical step in the biopharmaceutical manufacturing process aimed at ensuring the safety and purity of medicinal products, including vaccines, antibodies, and biologics. This method is employed to remove viral contaminants that could be harmful to human health. It is especially essential in the production of parenteral medications, which are introduced directly into the body and thus require high purity standards. Typically, specialized membrane filters with defined pore sizes are used to capture and remove viruses. These filters are designed to allow the passage of the desired product while effectively trapping viral particles. The process is rigorously validated before implementation, and periodic testing is performed to confirm its effectiveness. Furthermore, it serves as a robust safeguard in pharmaceutical manufacturing, enhancing product safety and compliance with regulatory requirements.
The global market is majorly driven by the escalating occurrence of global health crises such as pandemics and widespread viral outbreaks. This highlights the importance of this filtration technique to ensure the safety of medical supplies and pharmaceuticals. During such times, there is an exponential increase in the demand for vaccines and other therapeutic agents. This demand necessitates the mass production of biopharmaceuticals under tight schedules, without compromising on safety. Therefore, this is positively influencing the market. Along with this, the rise of contract manufacturing organizations (CMOs) in the biopharmaceutical industry is another significant factor contributing to the growth of the market. In addition, the escalating investments in the development of new medicines, therapies, and vaccines, which inherently require these processes for safety and compliance are also significantly supporting the market.
Increasing demand for biopharmaceuticals
One of the significant market drivers for the virus filtration industry is the growing demand for biopharmaceuticals such as monoclonal antibodies, recombinant proteins, and vaccines. These complex molecules are often derived from living cells, making them susceptible to viral contamination. Along with this, the rising prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders is impacting the market. This increase in demand places a burden on manufacturers to produce biopharmaceuticals that meet stringent safety and quality criteria. Virus filtration becomes an indispensable step in this scenario, as it is crucial for ensuring the purity and safety of these products. Regulatory bodies are imposing strict guidelines for viral clearance, further emphasizing the importance of these technologies. As more biopharmaceuticals enter the market or undergo clinical trials, the need for virus filtration services is accelerating correspondingly, thereby driving the industry forward.
Continual advancements in technology and research
Technological advancements in the field of filtration membranes and methods are significantly impacting the growth of the virus filtration industry. Along with this, the development of more efficient, scalable, and cost-effective filtration systems is making it easier for pharmaceutical companies to integrate these solutions into their existing production lines. Innovations in nanotechnology and material science are leading to filters with higher efficacy and better throughput capabilities, thus enabling more rapid and reliable virus removal. As research and development efforts continue in filtration technology, companies operating in this domain are increasing the adoption of the technology. This technological progress elevates the standard of pharmaceutical manufacturing and serves as a strong market driver for the global market.
An enhanced focus on regulatory compliance and quality assurance
Compliance with regulatory standards is a requirement and a market driver for the virus filtration industry. Agencies have specific guidelines about the viral safety of biologically-derived medicinal products. These guidelines often necessitate multiple steps for viral clearance, including virus filtration. Meeting these regulatory expectations is paramount for pharmaceutical companies to obtain product approvals and maintain market credibility. Given the dire consequences of viral contamination, ranging from delayed product launches to legal liabilities, the emphasis on regulatory compliance acts as a compelling force for the adoption of virus filtration technologies. Moreover, the industry benefits from this heightened focus on quality assurance, making it an essential component in the biopharmaceutical manufacturing value chain.
IMARC Group provides an analysis of the key trends in each segment of the global virus filtration market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, application, and end use.
Consumables
Kits and Reagents
Others
Instruments
Filtration Systems
Chromatography Systems
Services
Consumables hold the largest market share
The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables (kits and reagents, and others), instruments (filtration systems, chromatography systems), and services. According to the report, consumables accounted for the largest market share.
The market for consumables in the virus filtration industry is experiencing substantial growth, driven by the recurring need for filtration consumables, such as membranes, cartridges, and cassettes in the pharmaceutical manufacturing process. Unlike capital equipment that has a long lifecycle, consumables are used in a single manufacturing cycle and need frequent replacement, ensuring a consistent demand. Furthermore, the increasing adoption of single-use technologies, particularly in bioprocessing, amplifies the need for disposable filtration consumables, which are viewed as more convenient and less prone to cross-contamination. In addition, regulatory bodies are continually tightening the guidelines for viral safety in biopharmaceutical products, which, in turn, necessitates the use of high-quality consumables that meet these stringent standards. Moreover, the growing development and manufacturing of vaccines and therapies, especially during global health crises, including pandemics, drastically increase the consumption of these disposable products.
Biologicals
Vaccines and Therapeutics
Blood and Blood Products
Cellular and Gene Therapy Products
Others
Medical Devices
Water Purification
Air Purification
Others
Biologicals account for the majority of the market share
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes biologicals (vaccines and therapeutics, blood and blood products, cellular and gene therapy products, and others), medical devices, water purification, air purification, and others. According to the report, biologicals accounted for the largest market share.
The biologicals segment is a key application area driving the market, primarily due to the rising demand for biotherapeutic products, such as monoclonal antibodies, vaccines, and gene therapies. These complex molecules are produced in living cells, making them vulnerable to viral contamination, thereby necessitating robust filtration processes. Along with this, regulatory scrutiny over the safety of biological products is intensifying, with agencies mandating rigorous viral clearance steps. These regulatory imperatives enforce stringent quality controls, propelling the adoption of advanced virus filtration technologies in the biologicals domain. In addition, the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune conditions has also amplified the need for biotherapeutic treatments. Moreover, pharmaceutical companies are ramping up their production capacities and implementing state-of-the-art filtration methods to meet both consumer demand and regulatory requirements.
Biopharmaceuticals and Biotechnology Companies
Contract Research Organizations
Academic Institutes and Research Laboratories
Others
Biopharmaceuticals and biotechnology companies hold the largest market share
The report has provided a detailed breakup and analysis of the market based on the end use. This includes biopharmaceuticals and biotechnology companies, contract research organizations, academic institutes and research laboratories, and others. According to the report, biopharmaceuticals and biotechnology companies accounted for the largest market share.
The escalating demand for biopharmaceuticals and the rapid growth of biotechnology companies serve as pivotal market drivers in the virus filtration industry. These entities are at the forefront of developing complex biological products such as monoclonal antibodies, vaccines, and recombinant proteins, which are inherently susceptible to viral contamination. Additionally, the imperative for ensuring product safety and efficacy is a scientific necessity and a regulatory mandate. In confluence with this, organizations are setting stringent guidelines that require the application of robust virus filtration processes for quality assurance. As biopharmaceuticals become increasingly central in treating a range of diseases, from chronic conditions to pandemic-related illnesses, the need for effective virus filtration grows proportionally. Furthermore, advancements in biotechnology, such as CRISPR and gene therapy, have further extended the scope and complexity of bioproducts, subsequently amplifying the necessity for advanced virus filtration solutions.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest virus filtration market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest segment.
The market in North America is experiencing significant growth, propelled by a favorable environment for industry expansion. One of the leading drivers is the robust presence of global biopharmaceutical companies and advanced research institutions in the region, which necessitates high-quality virus filtration solutions for product safety. Along with this, regulatory frameworks set by agencies are enforcing stringent guidelines on viral clearance, thereby elevating the demand for efficient filtration technologies. In addition, North America has been a pioneer in biotechnological advancements, contributing to the development of new therapies, vaccines, and other bioproducts that require virus filtration.
Besides this, considerable growth in the investment in healthcare research and development is substantial in this region, further fueling the growth of the market. The occurrence of global health crises, such as pandemics, often leads to a rapid scale-up in vaccine and therapeutic production, dramatically increasing the need for reliable virus filtration systems. All these elements converge to make North America a strong market for virus filtration technologies, driving both innovation and adoption in the industry.
The key players are continually working on developing more efficient and reliable filtration technologies. This includes innovations in filter membranes, filtration systems, and single-use technologies to provide better solutions to clients. Along with this, the major companies are offering products and services that meet or exceed these regulations, often providing robust validation support for their customers. In addition, companies are entering into strategic partnerships or acquisitions to expand their geographical reach and product portfolio. Apart from this, several brands are offering consultancy services alongside their products to help customers optimize their filtration processes, which is acting as another growth-inducing factor. With an increasing focus on environmental responsibility, some companies are exploring and developing more sustainable filtration technologies, such as reusable or recyclable filter components.
Asahi Kasei Medical Co. Ltd.
Charles River Laboratories Inc.
Clean Cells
Danaher Corporation
Merck KGaA
Sartorius AG
Thermo Fisher Scientific Inc.
In March 2023, Charles River Laboratories Inc. announced the release of its off-the-shelf pHelper solution, which is intended to expedite and assure supplies for AAV-based gene therapy programs from the early stages of research to commercial manufacture.
In February 2022, Asahi Kasei Medical Co. Ltd. announced to build of a new assembly factory in Nobeoka, Miyazaki, Japan in order to increase the production capacity of PlanovaTM filters.
In September 2021, Clean Cells announced a €13 million ($15.3 million) investment in a new Montaigu-Vendee manufacturing facility. The organization supported by healthcare investment firm ArchiMed wants to play a significant part in accelerating the development and time-to-market of innovative medicines and vaccines for COVID-19 by quadrupling its analytical and production capacity for biopharmaceuticals.